MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 102 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NY\rdWFGTnWwY4Tpc44hSXO|YYm= NWrBOIdkOjVizszN M2jEcmROW09? M3fR[2lvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN MX[yOFY6PzR7Nh?=
HL-60 NGLsO3REgXSxdH;4bYMhSXO|YYm= NF\CPZg1OCEQvF2= MUm0PEBp M2jL[mROW09? M2PvNGlEPTB:MUCg{txO NWLDWGp4OjR4OUe0PVY>
SMMC-7721 Mkm1R5l1d3SxeHnjJGF{e2G7 NXfUN3RTPDBizszN M{TiZVQ5KGh? MUPEUXNQ M4O5Z2lEPTB;Nz6xJO69VQ>? Mo\ZNlQ3QTd2OU[=
A-549 M{DnSGN6fG:2b4jpZ{BCe3OjeR?= M3PJUVQxKM7:TR?= MWe0PEBp M2DYemROW09? MnzETWM2ODxzMDFOwG0> NFXMcJozPDZ7N{S5Oi=>
MCF-7 MmfqR5l1d3SxeHnjJGF{e2G7 MVW0NEDPxE1? NGHTR4U1QCCq MmXrSG1UVw>? NGS1bWNKSzVyPUeuN{DPxE1? MUOyOFY6PzR7Nh?=
SW-480 MX;DfZRwfG:6aXOgRZN{[Xl? NYrFRlRFPDBizszN MVi0PEBp M3qx[WROW09? NXTR[|JpUUN3ME20JO69VQ>? NV;IdFAxOjR4OUe0PVY>
NCI-H929 MmTCR5l1d3SxeHnjJGF{e2G7 NGHrNYQyKM7:TR?= MVe3NkBp MVLEUXNQ MY\JR|UxRTBwMUeg{txO NHyxV4QzPDZ{NUC4PC=>
293T MlXaR5l1d3SxeHnjJGF{e2G7 MYCxNEDPxE1? M2rpeFczKGh? MXrEUXNQ NF7KVItKSzVyPEKg{txO NH:0WYYzPDZ{NUC4PC=>
293T MW\GeY5kfGmxbjDBd5NigQ>? NVLtcHdnOTBizszN NIn3XIkzPCCq NVzZSWdwTE2VTx?= NXflO3hCVW:mZYLheIVtgSCrbnT1Z4V{KGinYYStd4hw[2tiIB?= MkfRNlQ3OjVyOEi=
HeLa NH3PTHZMcW6jc3WgRZN{[Xl? NHjkSIMyOCEQvF2= MYCxJIg> MUnEUXNQ MUjJcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5 M{\t[lI1OzJzOEOz
MDA-MB-231 NYDpV|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zVRVEh|ryP M4TtU|czKGh? MUDEUXNQ Mn;HTWM2OD1yLkG4JO69VQ>? NH;BN4ozPDF3M{KwOi=>
MCF-7 NH3BTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HUd|Eh|ryP M1r0fFczKGh? NXflbpg{TE2VTx?= NYLHWpFzUUN3ME2wMlE{KM7:TR?= M1n2clI1OTV|MkC2
MCF10A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxJO69VQ>? MoO4O|IhcA>? NVPz[YZCTE2VTx?= M4rqfmlEPTB;MD6yPUDPxE1? NVf0O|l5OjRzNUOyNFY>
HEK-293 MYLLbY5ie2ViQYPzZZk> NV;2NYhUOiCjbnSgNlAh|ryP MnS0NkBp M4\jNmROW09? MmiwTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i M{PqT|I{PTRyN{mw
Calu6 Mn\0SpVv[3Srb36gRZN{[Xl? MmLmNVAh|ryP NVHn[lRROThiaB?= M3fPTGROW09? NVPW[JlzW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> Mn:4NlM2ODZ2OE[=
IFN-gamma-induced RAW264.7 NE\ac45HfW6ldHnvckBCe3OjeR?= MXnEUXNQ MVnJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN M3Xrb|IzOjd5Mke3
IPC227F MmDFR5l1d3SxeHnjJGF{e2G7 NI\zOG4yKM7:TR?= NXHTcGhKPDhiaB?= MVnEUXNQ NUT0Nm4xUUN3ME2wMlA4PyEQvF2= NUfsTmM2OjF7MkS1Nlg>
Hepa-1c1c7 NGjVblBHfW6ldHnvckBCe3OjeR?= MnrFNlUh|ryP NF:2Ro03KGh? NYnO[5pnTE2VTx?= NW[5NmRLUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>? MVqyNFM6OjV2NB?=
COS-7 NFzHco1EgXSxdH;4bYMhSXO|YYm= NHrZ[5AyOCEQvF2= NYjPVGxoTE2VTx?= MkjPTWM2ODxzMDFOwG0> M4\0ZVE5ODh6MEm3
HuH-7 NG[2cI9EgXSxdH;4bYMhSXO|YYm= NXnZcnRqOTBizszN MmjiSG1UVw>? M1rsT2lEPTB:MUCg{txO NXn3VYR3OThyOEiwPVc>
OCI-Ly3 NVi4c5F[TnWwY4Tpc44hSXO|YYm= MVqxNEDPxE4EoB?= M4jYZVQhcA>? MlXRSG1UVw>? M4HzTmlv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP M3\EVVE5ODJ2MUGz
A2780 cDDP Mk\GRZBweHSxc3nzJGF{e2G7 NY\3d4ozOjRiaB?= NETDenlFVVOR MXTJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44> MVGxO|Y5PDBzOB?=
LPS-stimulated RAW264.7 cells NYO4fGxDTnWwY4Tpc44hSXO|YYm= MmjYSG1UVw>? Moi0TY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o MnrmNVc1ODd{N{e=
PC12 Ml[2SpVv[3Srb36gRZN{[Xl? MoewNVAxKM7:TdMg MUWyOEBp MoW1SG1UVw>? NUDJOVVEUW6qaXLpeJMhPi2RSFTBMUBidmRiSELPNk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MVKxO|E2QDR3NB?=
PC3 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTydppyOjBizszN MYi0PEBp MlW3SG1UVw>? MUHJR|UxRTBwNjFOwG0> MnXKNVY3QDZ3M{e=
LP-1 M2q5bmFxd3C2b4Ppd{BCe3OjeR?= M3fib|MxOCCwTR?= M{PxdFI1KGh? MVXEUXNQ Mo\KTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> MmTzNVU6PTh3OEm=
ES6 NIXm[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjlR4tKSzVyPUCuNFE{ODZizszN MVfTRW5ITVJ?
A101D M2n5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1yLkCzNlc6KM7:TR?= MV7TRW5ITVJ?
OCUB-M Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2cI13UUN3ME2wMlA{PzN5IN88US=> MYTTRW5ITVJ?
LB2518-MEL NV;BeWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEO3OkDPxE1? NFnGd5NUSU6JRWK=
SH-4 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1yLkC0N|Eh|ryP NHHyZ2JUSU6JRWK=
KNS-42 NEDNfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXneVV{UUN3ME2wMlA1PDRzIN88US=> MYHTRW5ITVJ?
DSH1 NWjFW4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fHcmlEPTB;MD6wOVI5QSEQvF2= NIi2dZRUSU6JRWK=
NTERA-S-cl-D1 NHHwSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XsSGlEPTB;MD6wOVc4OiEQvF2= NXTKdFdMW0GQR1XS
D-542MG NFfrWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLmTWM2OD1yLkC1PVU4KM7:TR?= MVvTRW5ITVJ?
KS-1 NH3pPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\XTmtKSzVyPUCuNFY1PThizszN MnPMV2FPT0WU
BL-41 NHvp[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCWmlEPTB;MD6wOlk1PyEQvF2= MoHWV2FPT0WU
LXF-289 M2\6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nYVmlEPTB;MD6wO|A3PiEQvF2= MXjTRW5ITVJ?
D-247MG NX:wVZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMEeyNFkh|ryP M3;WUXNCVkeHUh?=
MMAC-SF M2rsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1VGlEPTB;MD6wO|I3QCEQvF2= NVn2R2F7W0GQR1XS
CP66-MEL NInGNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TQ[2lEPTB;MD6wO|Uh|ryP MYTTRW5ITVJ?
LB771-HNC Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\vb2ZxUUN3ME2wMlA5ODN4IN88US=> MXjTRW5ITVJ?
no-10 NUXjc|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD1yLkC4PVA6KM7:TR?= MnjkV2FPT0WU
A388 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD1yLkC5NFY2KM7:TR?= MWTTRW5ITVJ?
OPM-2 NXHPOXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4N2lEPTB;MD6xNFQ4PCEQvF2= MXfTRW5ITVJ?
OVCAR-4 M{nVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjOO25KSzVyPUCuNVA6OzhizszN NVnVcVM4W0GQR1XS
HOP-62 M3LvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMUC5OFkh|ryP MkLYV2FPT0WU
ML-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rPOmlEPTB;MD6xNVgxPiEQvF2= NVLLNnRPW0GQR1XS
UACC-257 NXrHUHVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMUG5Nlch|ryP MYnTRW5ITVJ?
NEC8 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHjeYM5UUN3ME2wMlEyQTl3IN88US=> MUHTRW5ITVJ?
ONS-76 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMUK5N|Uh|ryP MY\TRW5ITVJ?
KE-37 NXT2[3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3POSmlEPTB;MD6xN|I4QCEQvF2= M4jxS3NCVkeHUh?=
HT-144 NFjocmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMUO4PVUh|ryP M4P2fnNCVkeHUh?=
LB2241-RCC M1TjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHsTWM2OD1yLkG0NlQ4KM7:TR?= NEDDbFlUSU6JRWK=
TE-5 NU\2W3Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMUSyO|gh|ryP Mne1V2FPT0WU
KINGS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjk[mpQUUN3ME2wMlE1PzlizszN MXrTRW5ITVJ?
NCI-H69 M1XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M324VWlEPTB;MD6xOVE1OSEQvF2= NYHBN|RDW0GQR1XS
CAS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3oTWM2OD1yLkG1OFgzKM7:TR?= NETzVY5USU6JRWK=
D-263MG NVLPOng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD1yLkG2NFA3KM7:TR?= MXrTRW5ITVJ?
A253 M3vwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrmTWM2OD1yLkG2NVI5KM7:TR?= NUfKfFdYW0GQR1XS
PF-382 M3fydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXQfI9KSzVyPUCuNVY4ODZizszN M3X6d3NCVkeHUh?=
CESS M2nKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMUewOkDPxE1? MX3TRW5ITVJ?
MZ2-MEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mTWM2OD1yLkG3OVU6KM7:TR?= MX7TRW5ITVJ?
HEL NUmwfXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jT[WlEPTB;MD6xPFUyPyEQvF2= NXjsVlFjW0GQR1XS
D-392MG M36zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmV3BoUUN3ME2wMlE6OTF3IN88US=> MlXpV2FPT0WU
SK-LMS-1 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\reWlEPTB;MD6xPVMxOyEQvF2= Mm[xV2FPT0WU
GI-ME-N NHXKR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLqTWM2OD1yLkG5N|A3KM7:TR?= M2XDOXNCVkeHUh?=
LB831-BLC M4G2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDDWJhbUUN3ME2wMlE6OzRizszN M1i5b3NCVkeHUh?=
DU-4475 NHnlUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpNoFKSzVyPUCuNVk3PThizszN NXnBU2d3W0GQR1XS
IST-SL1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XSWlEPTB;MD6yNFA6PCEQvF2= NXnpTXBjW0GQR1XS
GAK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzOWVFKSzVyPUCuNlA2OzRizszN MYjTRW5ITVJ?
EW-1 M1G5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v5emlEPTB;MD6yNVA1PyEQvF2= NXnIbIU2W0GQR1XS
LAMA-84 M4LGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRNGlEPTB;MD6yNVg2OSEQvF2= M1fUVnNCVkeHUh?=
SK-UT-1 M4G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTxe5FKSzVyPUCuNlIxPDlizszN NFi1XVRUSU6JRWK=
VA-ES-BJ M3vmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fJT2lEPTB;MD6yNlI2PyEQvF2= NV;Yd|c1W0GQR1XS
ACN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMkK2N|gh|ryP NVSwVm8zW0GQR1XS
SK-PN-DW MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vrT2lEPTB;MD6yN|E6KM7:TR?= NE\6U5FUSU6JRWK=
HD-MY-Z NH7iWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHRTWM2OD1yLkKzN|A{KM7:TR?= NGXTUJZUSU6JRWK=
LB373-MEL-D NUPXXFlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\afpR1UUN3ME2wMlI1OTl6IN88US=> MlPOV2FPT0WU
COLO-829 M3njbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jveGlEPTB;MD6yOFI2PyEQvF2= M3nVS3NCVkeHUh?=
ES8 NWnnNXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMkS3OlMh|ryP Mmq4V2FPT0WU
RXF393 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fOUGlEPTB;MD6yOVAyPSEQvF2= M13UN3NCVkeHUh?=
TK10 NXH3WIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPCPXk4UUN3ME2wMlI2PDN3IN88US=> M{DFXHNCVkeHUh?=
LOUCY M4m1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\DWGlEPTB;MD6yOVQ2PiEQvF2= NVLkS3V3W0GQR1XS
MZ7-mel M4j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr0TY9XUUN3ME2wMlI3Ozd2IN88US=> MmTFV2FPT0WU
CP67-MEL M{P5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPMTWM2OD1yLkK2O|Mh|ryP NVH2OY9kW0GQR1XS
C2BBe1 M{fFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHweYtXUUN3ME2wMlI4QTB5IN88US=> NFTudGdUSU6JRWK=
K052 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfBc4lCUUN3ME2wMlI5QTlizszN NXrufGlpW0GQR1XS
MOLT-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn0OIluUUN3ME2wMlI6PTJ2IN88US=> M3qxWXNCVkeHUh?=
KNS-81-FD NIGxboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvtTWM2OD1yLkOwN|I{KM7:TR?= NH7GeodUSU6JRWK=
CMK NFTN[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjpTWM2OD1yLkOxNVIh|ryP NFyxS4RUSU6JRWK=
LAN-6 NHPV[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETpO2dKSzVyPUCuN|E{KM7:TR?= MX;TRW5ITVJ?
KLE NWfWbVYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHja[JhKSzVyPUCuN|E{ODZizszN NYH5[plTW0GQR1XS
NCCIT NVOxR2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK1PIJIUUN3ME2wMlMyPzh|IN88US=> Mnr1V2FPT0WU
HH M2f5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD1yLkOyPFk4KM7:TR?= M3Hjb3NCVkeHUh?=
TE-8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\LZYVpUUN3ME2wMlM1Ojd7IN88US=> MUDTRW5ITVJ?
GDM-1 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\OfG1KSzVyPUCuN|UyODRizszN NFXFVllUSU6JRWK=
NCI-H747 NUWzRm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTyTWM2OD1yLkO3NVA{KM7:TR?= MWTTRW5ITVJ?
NCI-H1092 NX\aWJByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXiNodNUUN3ME2wMlM5QDR2IN88US=> MnLSV2FPT0WU
8-MG-BA M13FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfLTWM2OD1yLkO5PFM4KM7:TR?= Mof0V2FPT0WU
NB17 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNEK5O{DPxE1? NXnWWIh{W0GQR1XS
LC4-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK2TWM2OD1yLkSzOlA4KM7:TR?= MonzV2FPT0WU
TE-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrafYlKSzVyPUCuOFUyOTlizszN MkPtV2FPT0WU
KALS-1 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW4U4VpUUN3ME2wMlQ3PTh2IN88US=> NH7jN5FUSU6JRWK=
CCRF-CEM NVHPd4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHPbVVKSzVyPUCuOFc3PzRizszN MX\TRW5ITVJ?
OS-RC-2 NHj1UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHmSI1KSzVyPUCuOFc6PzJizszN M{PNU3NCVkeHUh?=
A704 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7leIRKSzVyPUCuOFg3QTJizszN MoG4V2FPT0WU
BB49-HNC NIjDN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTLTWM2OD1yLkS5NFk3KM7:TR?= M3L2RXNCVkeHUh?=
EVSA-T NGjje3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni2TWM2OD1yLkS5PVEyKM7:TR?= MVXTRW5ITVJ?
Mo-T MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjucYk6UUN3ME2wMlUyPzZ{IN88US=> NV7CZVI5W0GQR1XS
MONO-MAC-6 NIq5V2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KwRWlEPTB;MD61N|YyOSEQvF2= M2j6OHNCVkeHUh?=
BB65-RCC NE[yWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNU[4NVEh|ryP MlrZV2FPT0WU
NCI-H1882 M17qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTjTWM2OD1yLkW5NFM3KM7:TR?= Ml62V2FPT0WU
TE-9 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L3bmlEPTB;MD62NVA{OyEQvF2= M334ZnNCVkeHUh?=
NCI-H2126 M33TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwNkK2Olkh|ryP NUHzeW97W0GQR1XS
SF268 M3\memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DXW2lEPTB;MD62OVY1OSEQvF2= MVHTRW5ITVJ?
SW872 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3[WlYUUN3ME2wMlY2PzJ7IN88US=> MXTTRW5ITVJ?
LS-513 NILKXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37nNGlEPTB;MD62Olc2OSEQvF2= MWrTRW5ITVJ?
NCI-H1355 M2jIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fUNGlEPTB;MD62PFYyQSEQvF2= NWruWnlrW0GQR1XS
BL-70 M1fGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3lTWM2OD1yLk[5N|g5KM7:TR?= NIDzdHFUSU6JRWK=
NCI-SNU-5 M2DZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHxc3lKSzVyPUCuOlk2PDVizszN NInr[WdUSU6JRWK=
SNU-C2B NUTuXWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwN{C3N|kh|ryP NWXwe4dUW0GQR1XS
GB-1 NUTH[FFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTwV4RKSzVyPUCuO|IyOjRizszN NWnyO4xqW0GQR1XS
CTB-1 NXPRNnJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwN{e5OVUh|ryP NVvYXYRtW0GQR1XS
Becker NHrkZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwN{m2NlEh|ryP MWDTRW5ITVJ?
KM12 NEW1cXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDS3FMUUN3ME2wMlg2PDZ4IN88US=> NELpTpRUSU6JRWK=
ES7 NF74NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD1yLki5OlUh|ryP M1TJcnNCVkeHUh?=
COLO-684 NHzUWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL0RoJKSzVyPUCuPVA3PThizszN MXvTRW5ITVJ?
HCC2998 M3ewWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUO4OVQh|ryP M1;wfHNCVkeHUh?=
TE-10 M3fUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPZc29KSzVyPUCuPVY1OyEQvF2= NGjzSppUSU6JRWK=
SF126 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16yeWlEPTB;MD65PFk4OSEQvF2= Ml;NV2FPT0WU
EKVX M{G2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnqTWM2OD1zLkCzOFQzKM7:TR?= MUHTRW5ITVJ?
KARPAS-45 M1WxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzZTWM2OD1zLkC0NFE3KM7:TR?= MofIV2FPT0WU
KGN NUfUZ4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwMEWwOFUh|ryP MmjzV2FPT0WU
ES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DtfmlEPTB;MT6wO|kzOSEQvF2= MYjTRW5ITVJ?
L-540 M1rwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFwMUG4N|kh|ryP NUXIWJhYW0GQR1XS
KURAMOCHI MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwMUKzO|Qh|ryP M4jYVHNCVkeHUh?=
LU-65 NXP5RVZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPFcm1HUUN3ME2xMlEzPzV|IN88US=> MXLTRW5ITVJ?
MFH-ino MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMUe1NFEh|ryP M1LQcHNCVkeHUh?=
NCI-H23 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HPeWlEPTB;MT6yNFQyKM7:TR?= NFu0Z2VUSU6JRWK=
IA-LM MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm0PHd1UUN3ME2xMlI1OTF4IN88US=> MV\TRW5ITVJ?
PSN1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiyW|FKSzVyPUGuNlcxOTZizszN NYLzb5VqW0GQR1XS
NCI-H719 NULLUYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInNRndKSzVyPUGuNlc1OTFizszN M3zJd3NCVkeHUh?=
SW684 NWrtWZRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHETWM2OD1zLkK4OlU6KM7:TR?= NGfxeWxUSU6JRWK=
HCE-4 NHLLdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFwM{CyNlEh|ryP NHP2WGpUSU6JRWK=
EW-16 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwe2lEPTB;MT6zNVM1PyEQvF2= NIrLUlhUSU6JRWK=
NCI-H128 NUDQblcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jRXWlEPTB;MT6zOVgyPCEQvF2= M2\pN3NCVkeHUh?=
HC-1 NGLvRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof5TWM2OD1zLkO4NVch|ryP NFzjUZlUSU6JRWK=
IST-MES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNECyNFgh|ryP MlPLV2FPT0WU
Raji M1rYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwNEG4OUDPxE1? NXLBO|B6W0GQR1XS
DMS-114 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jRfWlEPTB;MT60OFU{QSEQvF2= MlfHV2FPT0WU
GI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXBfnhTUUN3ME2xMlQ4OTNzIN88US=> Mn3CV2FPT0WU
NCI-H2081 M1rtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwNUWxPVYh|ryP MWnTRW5ITVJ?
LC-1F M2Tv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHqO|BKSzVyPUGuOVUyQThizszN M4r4[XNCVkeHUh?=
NCI-H2227 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\pfWlEPTB;MT62NVU3OSEQvF2= NVnpdGl2W0GQR1XS
D-502MG NWHybJFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwNkeyNVEh|ryP Ml\XV2FPT0WU
NCI-H2141 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwNkezNVch|ryP M3L2cHNCVkeHUh?=
LS-411N NFv3dnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmzTItbUUN3ME2xMlY6QDB5IN88US=> NFfrUVdUSU6JRWK=
SU-DHL-1 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3iTWM2OD1zLkexNlgyKM7:TR?= MXTTRW5ITVJ?
BB30-HNC MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwN{K2PFUh|ryP M1rzPHNCVkeHUh?=
TE-15 NEXCS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF36OpFKSzVyPUGuPVI{PzNizszN MXjTRW5ITVJ?
JVM-3 NUS2T2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwOUO5NFQh|ryP NX3VZmVYW0GQR1XS
IST-SL2 M1\HUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF36WmxKSzVyPUKuNFEzPTJizszN MUPTRW5ITVJ?
EW-18 M4\Ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnHN3I2UUN3ME2yMlAzOzN5IN88US=> NILGbGZUSU6JRWK=
DJM-1 NVzBZWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjKTWM2OD1{LkCyOVUzKM7:TR?= M2rNTXNCVkeHUh?=
no-11 M{ftcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LhOmlEPTB;Mj6wN|ExPCEQvF2= MnztV2FPT0WU
QIMR-WIL M4[yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4Xm1KSzVyPUKuNVY4PjJizszN NEO0UndUSU6JRWK=
MC-CAR NIPocFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\lTWM2OD1{LkKyPVUh|ryP MWjTRW5ITVJ?
KM-H2 NV3tdFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m5R2lEPTB;Mj6yPVA1OyEQvF2= Mn;kV2FPT0WU
ECC12 M4rSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;NbGlEPTB;Mj6zO|k1KM7:TR?= NEizR3ZUSU6JRWK=
HCE-T NYf3ZmNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwNES4PFMh|ryP NUfrSXMyW0GQR1XS
MFM-223 NH;zU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILI[JJKSzVyPUKuOVA5PzFizszN MX3TRW5ITVJ?
SW982 M37kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1{LkWxOFgh|ryP MljxV2FPT0WU
KG-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwOEi3PVEh|ryP Moi1V2FPT0WU
ES4 M3KyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCxTWM2OD1|LkC2NVEyKM7:TR?= MVHTRW5ITVJ?
SCC-3 NV3GSolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPWGNuUUN3ME2zMlExQDR6IN88US=> M{HYZnNCVkeHUh?=
RH-1 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LTfWlEPTB;Mz6zPFc1QCEQvF2= MYfTRW5ITVJ?
NCI-H748 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\iSWlEPTB;Mz60OFI3PiEQvF2= MWfTRW5ITVJ?
HCC2218 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD1|LkS2PVM4KM7:TR?= NV3X[Yc6W0GQR1XS
MEG-01 M2\s[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvLV3JKSzVyPUOuOVk3QCEQvF2= NYfTRpB3W0GQR1XS
NB12 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4[FBWUUN3ME2zMlU6QDh6IN88US=> NVzScpJFW0GQR1XS
SNB75 NYmwTJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;TTWM2OD1|Lk[wNVA{KM7:TR?= MUTTRW5ITVJ?
KMS-12-PE M4\Qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy4dotKSzVyPUOuOlc4OjNizszN NWG2fG44W0GQR1XS
SKM-1 M{KycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfwTWM2OD1|LkexN|c3KM7:TR?= MkjsV2FPT0WU
COLO-320-HSR NYOxWZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXOTWM2OD1|Lke1OlM1KM7:TR?= Mn\IV2FPT0WU
NKM-1 NEfVcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDNTWM2OD1|Lke3N|c5KM7:TR?= NXLWTGxuW0GQR1XS
TE-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33sS2lEPTB;Mz65OFU3OSEQvF2= MlrYV2FPT0WU
D-336MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwMEGxOlYh|ryP NX3p[VZpW0GQR1XS
NCI-H1650 NFTDTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3VWxKSzVyPUSuNVU4QTdizszN Ml3lV2FPT0WU
ES3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nCdGlEPTB;ND6zNlgzPCEQvF2= M2rSOXNCVkeHUh?=
YT MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwM{W0NlQh|ryP NIXuU|NUSU6JRWK=
ES5 M4Ptbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi3TWM2OD12LkSwNlU2KM7:TR?= Ml3qV2FPT0WU
LB647-SCLC NHqzOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSwS2NKSzVyPUSuOVY{ODhizszN MV7TRW5ITVJ?
HAL-01 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRwNUewN|Qh|ryP M{S2XnNCVkeHUh?=
LP-1 NUjBN2xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DpV2lEPTB;ND63NlM4OSEQvF2= NYfhWGpSW0GQR1XS
BC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDlXotKSzVyPUWuNFA1PDdizszN NUjSN4pYW0GQR1XS
EB-3 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPWSIpKSzVyPUWuNFMxPDFizszN NWfSWo12W0GQR1XS
GT3TKB MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO3TWM2OD13LkG3OlYzKM7:TR?= MmDvV2FPT0WU
NCI-H209 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33FZ2lEPTB;NT6xPVM2OiEQvF2= MkPzV2FPT0WU
BT-474 NIPjU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnGNW1KSzVyPUWuNlMyODJizszN MoLBV2FPT0WU
RKO MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG2TWM2OD13LkKzOFIzKM7:TR?= MXjTRW5ITVJ?
SIMA MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\jTWM2OD13LkOwO|Y2KM7:TR?= M1fvXXNCVkeHUh?=
RL NW[4dYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hq[GlEPTB;NT6zO|U1OSEQvF2= Mon4V2FPT0WU
GCIY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPhTWM2OD13LkS3NlM3KM7:TR?= MXXTRW5ITVJ?
Calu-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwNkKyJO69VQ>? NUTWdIczW0GQR1XS
ALL-PO NHrUZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTVwNkO3PVUh|ryP NFm5R5dUSU6JRWK=
ARH-77 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVwNkewPFch|ryP NFLzeoRUSU6JRWK=
A4-Fuk MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GydWlEPTB;Nj6wPFEyQCEQvF2= MV;TRW5ITVJ?
NCI-H1581 M4XuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrUc|NKSzVyPU[uNlM5PDlizszN MUjTRW5ITVJ?
HUTU-80 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZwM{[4PVch|ryP NULiSJhjW0GQR1XS
TGW NF:4ZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrZbXVKSzVyPU[uOFU2QTNizszN MV3TRW5ITVJ?
SK-N-FI NGTSdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzTWM2OD14LkS1PFU1KM7:TR?= MX;TRW5ITVJ?
U-266 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXribIZEUUN3ME22MlUyQTJ4IN88US=> NWDKS3VXW0GQR1XS
EM-2 NXvvOHM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfRcYtKSzVyPU[uOlcxQTlizszN MUDTRW5ITVJ?
NMC-G1 NW\sVpJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfRboJOUUN3ME22MlcyQDl3IN88US=> NI\DdnNUSU6JRWK=
KASUMI-1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn3SnpuUUN3ME22Mlg1Pzh5IN88US=> NEHuTZdUSU6JRWK=
NALM-6 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lid2lEPTB;Nj64Olc2PCEQvF2= MojhV2FPT0WU
OCI-AML2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\BcYdFUUN3ME23MlAxOzJ4IN88US=> MXjTRW5ITVJ?
SHP-77 NF;nTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLsdWpUUUN3ME23MlIzPDNizszN M4\xN3NCVkeHUh?=
NOMO-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfUN|R1UUN3ME23MlI1OjV2IN88US=> NVLMO2RPW0GQR1XS
SK-N-DZ M4HjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPO|NHUUN3ME23MlcyODh7IN88US=> NUDEcYRWW0GQR1XS
LB1047-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\NTWM2OD15LkeyNlMyKM7:TR?= M1TXR3NCVkeHUh?=
MZ1-PC Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTdwOE[1OVgh|ryP NEXLXHNUSU6JRWK=
NB10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\zeG9KSzVyPUeuPVk2PTZizszN Mof3V2FPT0WU
RL95-2 NYTTOncyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TJfGlEPTB;OD6xNFg1OiEQvF2= NYTYUpJ[W0GQR1XS
OMC-1 NYDqflZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M123Z2lEPTB;OD61NlE6OSEQvF2= NWnK[YNvW0GQR1XS
D-283MED MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PrfGlEPTB;OD65NVcyQSEQvF2= M13n[HNCVkeHUh?=
MC116 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLXUncxUUN3ME24Mlk4QTRizszN MU\TRW5ITVJ?
SJSA-1 NGjVZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\O[2NKSzVyPUmuNFkxQTFizszN MmK1V2FPT0WU
JiyoyeP-2003 NWTjenluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7wNXpKSzVyPUmuNlk{OTdizszN MYXTRW5ITVJ?
IST-MEL1 NIDSeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyxTWM2OD17Lke0NVk5KM7:TR?= NILVNVVUSU6JRWK=
CTV-1 M{XKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPaWnpKSzVyPUGwMlA6PzlizszN NGC5XW9USU6JRWK=
NH-12 NXXNXHd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHoTWM2OD1zMD6yOFM{KM7:TR?= Mk\SV2FPT0WU
CA46 NFPEOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoiyTWM2OD1zMD6zOlEh|ryP MWXTRW5ITVJ?
NCI-SNU-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm0NXJKSzVyPUGwMlQ6PjlizszN NH64SXBUSU6JRWK=
SCLC-21H NUW4S4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD1zMD62OVk3KM7:TR?= NWX6c2JEW0GQR1XS
EC-GI-10 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\LeYdUUUN3ME2xNE44ODNzIN88US=> MXTTRW5ITVJ?
SR MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzLkCxPFUh|ryP MWPTRW5ITVJ?
NCI-H1648 NWjVT5p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLkC5OlUh|ryP NYn5eI1oW0GQR1XS
TGBC1TKB NGPwcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf6TWM2OD1zMT60NVAzKM7:TR?= NWDx[|dYW0GQR1XS
EW-11 NFH3UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPJT5puUUN3ME2xNU42OTh4IN88US=> MVLTRW5ITVJ?
SK-MM-2 NWTBempST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy5UZlrUUN3ME2xNU45ODZzIN88US=> MVfTRW5ITVJ?
NCI-H524 NHnz[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OzOWlEPTB;MUGuPVgzOiEQvF2= NFmzOHNUSU6JRWK=
NOS-1 NU[3XGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS2TWM2OD1zMj6wN|Q2KM7:TR?= M2H2PXNCVkeHUh?=
AM-38 M2ezU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\6VJpKSzVyPUGyMlU3OzNizszN MoD4V2FPT0WU
A498 NV2zSZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm1TWM2OD1zMj63NFY6KM7:TR?= NIjLOnVUSU6JRWK=
KARPAS-422 NX\0PYxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHsOG5KSzVyPUGyMlc1QTZizszN MmjuV2FPT0WU
LU-139 NWfJZYE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrGTWM2OD1zMj65NFI3KM7:TR?= NH64OlVUSU6JRWK=
COR-L88 NW\VUmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fMd2lEPTB;MUKuPVM5OiEQvF2= NHHzeFBUSU6JRWK=
K5 NHTXVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPjOZJFUUN3ME2xNk46PDZ{IN88US=> MX\TRW5ITVJ?
NB13 M2ToO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD1zMj65O|g{KM7:TR?= M{XxenNCVkeHUh?=
MRK-nu-1 NEPsRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;6OmhTUUN3ME2xN{4yQTVizszN MXTTRW5ITVJ?
MHH-NB-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfF[pJKSzVyPUGzMlI6ODJizszN NFO0OpVUSU6JRWK=
KU812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H4XmlEPTB;MUOuOlEzPCEQvF2= NWH0bWlIW0GQR1XS
TE-12 M3XvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLTfWtKSzVyPUGzMlY6QTRizszN M2TrVnNCVkeHUh?=
NCI-N87 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF|LkezOkDPxE1? Ml;sV2FPT0WU
EB2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF|Lki1NFUh|ryP NWTFWVVWW0GQR1XS
DB MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF|Lkm4PFUh|ryP M4WxeHNCVkeHUh?=
697 NFLvZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF2LkS1NVEh|ryP NHvGS|NUSU6JRWK=
MSTO-211H MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTtTWM2OD1zND63OFQ5KM7:TR?= MmPZV2FPT0WU
JVM-2 NVG4UVRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLuXINiUUN3ME2xOE44PzN3IN88US=> NVvkfHhCW0GQR1XS
COLO-824 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorvTWM2OD1zND63PVk1KM7:TR?= NVPJVo17W0GQR1XS
BC-3 NEjFcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF3LkO5PEDPxE1? MVvTRW5ITVJ?
BOKU MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzRTWM2OD1zNT65OlA5KM7:TR?= MlzaV2FPT0WU
GOTO NHvaPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi0TWM2OD1zNj65OlE4KM7:TR?= M1vITXNCVkeHUh?=
HCC2157 M4\m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL6TWM2OD1zNz60O|U2KM7:TR?= MkTOV2FPT0WU
LS-1034 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7oTWM2OD1zNz62PFE5KM7:TR?= M3;mbnNCVkeHUh?=
CAL-148 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjqTWM2OD1zNz65O|k3KM7:TR?= MUTTRW5ITVJ?
MOLT-4 NGTNcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknNTWM2OD1zOD64NlA5KM7:TR?= MVzTRW5ITVJ?
Daudi NYHmdoFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF6LkmyN|Eh|ryP MnPhV2FPT0WU
J-RT3-T3-5 NX\IVI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF7LkSwOlYh|ryP MX3TRW5ITVJ?
KMOE-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\nfWlEPTB;MUmuOlQ5OiEQvF2= NHrIOFZUSU6JRWK=
HL-60 M1vldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLTWnR3UUN3ME2yNE4yQTZ3IN88US=> M2H6XnNCVkeHUh?=
P31-FUJ MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[yTWM2OD1{MD60O|U{KM7:TR?= MWfTRW5ITVJ?
IM-9 NULrOopKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\VWmlEPTB;MkCuOlIzPCEQvF2= M3nxXnNCVkeHUh?=
HDLM-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJyLki4NlEh|ryP NYrDW3dKW0GQR1XS
NCI-H1304 NVjsdYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5[GlEPTB;MkGuNFMyOSEQvF2= MW\TRW5ITVJ?
NCI-H345 M4O1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT5NY1pUUN3ME2yNU4xPjR|IN88US=> MnjaV2FPT0WU
RPMI-6666 M1\XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJzLkO2NFIh|ryP Moi5V2FPT0WU
GR-ST M{nPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS3W4FlUUN3ME2yNU41OTdizszN NUnHZY1FW0GQR1XS
CHP-126 M3XyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJzLk[xPFEh|ryP NYLyXpoyW0GQR1XS
EHEB NW\EeolkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfCTWM2OD1{MT62O|MyKM7:TR?= NVroe2xiW0GQR1XS
CPC-N NHXGbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ2LkCyNFEh|ryP NVP4XYQ6W0GQR1XS
NB1 NGrj[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr0[5JKSzVyPUK0MlY6OzlizszN MWXTRW5ITVJ?
LS-123 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XkTmlEPTB;MkSuPVAyOiEQvF2= NFjsRZFUSU6JRWK=
ST486 M2GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;Jb2lEPTB;MkWuNVEyOyEQvF2= MY\TRW5ITVJ?
NCI-H1963 NEDK[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ4LkC2NlMh|ryP M3uzbHNCVkeHUh?=
U-87-MG NVLNcI5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3VeI5UUUN3ME2yOk44PjR2IN88US=> M{HoN3NCVkeHUh?=
COR-L279 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D6UmlEPTB;Mk[uO|kzOiEQvF2= MWnTRW5ITVJ?
LU-165 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfHSXI1UUN3ME2yPE4xQDZzIN88US=> MYHTRW5ITVJ?
COLO-800 NUDxWXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJ6LkK5OVYh|ryP NXf0TotsW0GQR1XS
ETK-1 NX3CdJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\mZ2VKSzVyPUK4MlM1PDZizszN Mn3RV2FPT0WU
LNCaP-Clone-FGC MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjCSnRGUUN3ME2yPU46OjhzIN88US=> NXjEbYFSW0GQR1XS
SIG-M5 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TicmlEPTB;M{CuO|k2OiEQvF2= M3XoZ3NCVkeHUh?=
NB6 M1zKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LzSGlEPTB;M{CuPVUxOyEQvF2= MYLTRW5ITVJ?
NCI-H2107 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrsW|dsUUN3ME2zNU4zOzN6IN88US=> Ml;uV2FPT0WU
SNU-C1 NYjyZVhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PuSGlEPTB;M{GuN|EzPiEQvF2= M1H1PHNCVkeHUh?=
JAR NWLMe5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNzLkO3PVkh|ryP MX7TRW5ITVJ?
L-363 M4rxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnZ2lEPTB;M{KuNlE1PCEQvF2= M3LZVnNCVkeHUh?=
EW-24 NHnyVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HBW2lEPTB;M{KuN|Q4PCEQvF2= MkTUV2FPT0WU
NB69 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnRVVVKSzVyPUOzMlY1PTRizszN Mm\BV2FPT0WU
EW-13 NESydFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjKXpBKSzVyPUOzMlg6PjlizszN M3;p[XNCVkeHUh?=
Ramos-2G6-4C10 M3Tl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTmfXZqUUN3ME2zOE4zQTl|IN88US=> NYfzUY45W0GQR1XS
TE-11 NFv3clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPlVHh[UUN3ME2zOE41QDJ{IN88US=> NVftVZA3W0GQR1XS
L-428 NEDhU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrObYVFUUN3ME2zOE44PTN4IN88US=> Mnu4V2FPT0WU
KP-N-YN M3XuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjsTWM2OD1|ND65NFU4KM7:TR?= MXTTRW5ITVJ?
CGTH-W-1 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7vTWM2OD1|Nj65NFQ5KM7:TR?= NFnPUXlUSU6JRWK=
K-562 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorHTWM2OD1|Nz6wPFY1KM7:TR?= MYnTRW5ITVJ?
NCI-H1299 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHUTWM2OD1|OD6xOlA{KM7:TR?= M4P5S3NCVkeHUh?=
RCC10RGB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fBcGlEPTB;M{iuNlA5OyEQvF2= NVrPVYxGW0GQR1XS
NCI-SNU-16 NEXWc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonwTWM2OD1|OD61OlU{KM7:TR?= M{PrfHNCVkeHUh?=
LC-2-ad MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLMTWM2OD1|OT60N|M4KM7:TR?= M17LSHNCVkeHUh?=
MHH-PREB-1 NV3QZ5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN7LkezPFgh|ryP M3TjV3NCVkeHUh?=
NCI-H64 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkTWM2OD12MD6wPVQ5KM7:TR?= NXrBb4k1W0GQR1XS
LB996-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;WZ255UUN3ME20NE45PzF4IN88US=> MknMV2FPT0WU
DEL NU[2R2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqxfmI1UUN3ME20NU41PDB3IN88US=> MY\TRW5ITVJ?
MLMA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPsN5BMUUN3ME20NU44PTl3IN88US=> NXrsUlBTW0GQR1XS
SBC-1 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwPWlEPTB;NEKuNVgxPiEQvF2= MmjEV2FPT0WU
MPP-89 NIrZd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L0cmlEPTB;NEKuOVg4PSEQvF2= MlfLV2FPT0WU
MV-4-11 NGOzS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR{LkmwOlch|ryP NUnjdXdrW0GQR1XS
EoL-1- NFnw[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jIbWlEPTB;NESuNVU3QCEQvF2= NE\P[nNUSU6JRWK=
CW-2 NF;Ge2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH5TWM2OD12ND64N|QzKM7:TR?= NEjCTZpUSU6JRWK=
HT NF;BfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR3LkewNFch|ryP MXTTRW5ITVJ?
SW954 NYrpSYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSTWM2OD12Nz60NVI5KM7:TR?= NI\VXVJUSU6JRWK=
A3-KAW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXrTWM2OD12OT64NFYyKM7:TR?= NFTBboRUSU6JRWK=
TC-YIK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHhTWM2OD13MD6wN|Y{KM7:TR?= MlnTV2FPT0WU
SW962 NWjqeY9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTV2LkizOVch|ryP NGDhZ21USU6JRWK=
KP-N-RT-BM-1 NXrvdVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiZZRKSzVyPUW2MlY3OzhizszN NH;mVIFUSU6JRWK=
NCI-H1395 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxTWM2OD13OD64NVczKM7:TR?= MorYV2FPT0WU
RPMI-8402 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvFbYVKSzVyPUW4Mlk2OjZizszN NFjkSo9USU6JRWK=
SCH M3j1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZyLkm2N|gh|ryP MULTRW5ITVJ?
NCI-H2196 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXqTWM2OD14MT6yN|Eh|ryP Mm\DV2FPT0WU
LOXIMVI Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfY[IhKSzVyPU[xMlgzPjZizszN MWjTRW5ITVJ?
TGBC24TKB MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHWbW5KSzVyPU[yMlE1QTFizszN MWrTRW5ITVJ?
SK-MEL-2 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3EUFZKSzVyPU[zMlk5QTJizszN MUPTRW5ITVJ?
U-698-M NFH0XGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITpZoNKSzVyPU[4MlU3QDdizszN Mn[0V2FPT0WU
NCI-H1522 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1PWJKSzVyPU[5MlAxPDdizszN MVjTRW5ITVJ?
UACC-812 NUfNRocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZ7LkWyNFkh|ryP NYHZZWltW0GQR1XS
MHH-CALL-2 M{XGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[4fFZEUUN3ME23NE4xPiEQvF2= NYm5XpVqW0GQR1XS
NB5 NECwWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTPTWM2OD15MD6zOFY5KM7:TR?= NGPCN3ZUSU6JRWK=
KARPAS-299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTdyLkS0OFch|ryP NE\JcYxUSU6JRWK=
NCI-H1694 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjOTWM2OD15MT6wN|Ih|ryP MU\TRW5ITVJ?
NCI-H82 NGHVOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD15MT65OVA4KM7:TR?= M2XyVXNCVkeHUh?=
SCC-15 NEG0SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vF[GlEPTB;N{KuN|Qh|ryP M13rVnNCVkeHUh?=
NCI-H1436 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTd{Lke0OVYh|ryP MmW5V2FPT0WU
ATN-1 M2XiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTqTWM2OD15ND61NFUh|ryP M2TzTXNCVkeHUh?=
RPMI-8866 M3LjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD3TWM2OD15ND63OVA6KM7:TR?= M33I[nNCVkeHUh?=
HCC1599 NXPrSVc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDyTWM2OD15ND64O|MzKM7:TR?= MXjTRW5ITVJ?
NCI-H1155 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTd2LkmzOlch|ryP NGXhS3dUSU6JRWK=
DOHH-2 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HjPGlEPTB;N{SuPVUyPCEQvF2= NX7uXo4yW0GQR1XS
SK-NEP-1 NE[4bJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHKTWM2OD15NT6wO|U1KM7:TR?= NUHIcJY4W0GQR1XS
HCC1187 NYr2eHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfUcmlKSzVyPUe3MlYyOjJizszN NVvEdYtoW0GQR1XS
NCI-H322M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\VTWM2OD15OD6zO|A6KM7:TR?= M2fEUXNCVkeHUh?=
NCI-H526 NE\5PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTd6LkW4O|ch|ryP MX7TRW5ITVJ?
NCI-H2171 NWPXfm1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqO2drUUN3ME23PU41OTN4IN88US=> NUDBSWFwW0GQR1XS
COLO-668 NHfH[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLuZZV6UUN3ME24NU42QDh2IN88US=> NHjvTIVUSU6JRWK=
RS4-11 M2n3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\wUGEzUUN3ME24Nk4zPTB3IN88US=> Ml3GV2FPT0WU
NCI-H716 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLES4ZKSzVyPUiyMlkxPzVizszN MUTTRW5ITVJ?
LU-134-A NYDvc|diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTh|LkGzOVEh|ryP MmTOV2FPT0WU
RPMI-8226 NHvXTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Wb29KSzVyPUi0MlIyODdizszN NHfCO4xUSU6JRWK=
KY821 NFfKNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33VfWlEPTB;OUGuOlU2OSEQvF2= MUDTRW5ITVJ?
ECC4 NFHPTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf3PIVKSzVyPUmzMlgzPjlizszN NWLObm1nW0GQR1XS
EW-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkO3lKSzVyPUm0MlkxQDFizszN MUDTRW5ITVJ?
NB7 NFX5e5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTaO2hKSzVyPUm1Mlc4QDZizszN Ml3aV2FPT0WU
NCI-H720 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTl6LkSwOlEh|ryP NXPaWHZ[W0GQR1XS
NCI-H446 M4TJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;6TWM2OD17OT63OVg5KM7:TR?= NH3DOmhUSU6JRWK=
NCI-H889 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7mTWlKUUN3ME2xNFQvOjR{IN88US=> MXrTRW5ITVJ?
EW-22 M1TZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zKdWlEPTB;MUC2MlE6KM7:TR?= NUHUWIVYW0GQR1XS
BV-173 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyOmlEPTB;MUC4MlczQCEQvF2= MluwV2FPT0WU
WSU-NHL NVzQTFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFyOT62O|Eh|ryP M33lPHNCVkeHUh?=
MN-60 M2DN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jhSGlEPTB;MUC5MlY6KM7:TR?= NGDPXW9USU6JRWK=
DG-75 NUDMVXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf6TWM2OD1zMUOuN|UzKM7:TR?= MVPTRW5ITVJ?
DMS-79 NYLOc|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[5T2hKSzVyPUGxO{4{QDJizszN NUfpcXN2W0GQR1XS
SK-MEL-1 NUn4SVN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrzflBKSzVyPUGxPE4xODlizszN MWXTRW5ITVJ?
DMS-153 M2rzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTNTWM2OD1zMkGuO|Q2KM7:TR?= M4f1WHNCVkeHUh?=
NCI-H510A MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fDbGlEPTB;MUK3MlMzKM7:TR?= MWrTRW5ITVJ?
BE-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP6TWM2OD1zM{SuNFQ1KM7:TR?= NU\RTXp3W0GQR1XS
KP-N-YS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1zM{muO|M3KM7:TR?= M1T1RXNCVkeHUh?=
SUP-T1 NFvmRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF2Mz63NFgh|ryP MY\TRW5ITVJ?
EW-12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofzTWM2OD1zNESuOlk6KM7:TR?= MY\TRW5ITVJ?
NB14 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLVXI5KSzVyPUG0O{4xQDJizszN NH7yd41USU6JRWK=
MDA-MB-134-VI NU\yPYNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C1OGlEPTB;MUS4MlI3QCEQvF2= MkP0V2FPT0WU
NCI-H1770 NVnsUFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LUdWlEPTB;MUW2MlI4QSEQvF2= NETZVINUSU6JRWK=
TUR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj0TWM2OD1zNkeuPFch|ryP MUTTRW5ITVJ?
NCI-H1417 NYfX[|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\jXIQyUUN3ME2xPFAvOzNzIN88US=> NX[0RoN6W0GQR1XS
IMR-5 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF6MT61O|Eh|ryP NIfDOFNUSU6JRWK=
NCI-H226 M{e4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTHTWM2OD1zOEiuPFY3KM7:TR?= M1mzW3NCVkeHUh?=
NCI-H187 NYn3Wnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPRTWM2OD1zOUCuNFY1KM7:TR?= M1HNZ3NCVkeHUh?=
SF539 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF7Mj63Nlgh|ryP MlL2V2FPT0WU
TALL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FcoRSUUN3ME2xPVgvOzB2IN88US=> M3W1RnNCVkeHUh?=
TE-441-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrUGZ4UUN3ME2xPVkvPzN7IN88US=> NXfsbZN7W0GQR1XS
REH MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKZ2lEPTB;MkO2MlYzPiEQvF2= NFH5[oRUSU6JRWK=
MS-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[4NZZtUUN3ME2yN|kvOTJzIN88US=> MYjTRW5ITVJ?
THP-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFTWM2OD1{NkSuO|M5KM7:TR?= M3\KTHNCVkeHUh?=
NCI-H1838 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ5MT60OVYh|ryP NGS3VpJUSU6JRWK=
P30-OHK NYnQ[oZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ6Mz64OFch|ryP MVPTRW5ITVJ?
C8166 NF\qPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0TWM2OD1|NEWuN|M5KM7:TR?= NXTOSFdvW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products4

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID